knock knock, page-590

This is a good write up

You’re Missing Out: 3 Top Cannabis Biotech Stocks

https://thegreenfund.com/top-3-cannabis-biotech-stocks

MGC Pharma

MGC Pharmaceuticals Ltd (ASX:MXC), another Australian-listed cannabis biotech company, operates a European-based ‘Seed to Pharma’ model, as they develop, produce and distribute Cannabinoid-based active pharmaceutical ingredients (API).

Their Maltese facility is euGMP certified, which means the entire European continent is now a potential client, as only euGMP-certified medicinal cannabis can be bought and sold in Europe. In addition, the company was also the first to be granted qualification for its medicinal drugs by the European Medicines Agency.

What this means is that the company now has a green light to apply for the evaluation and registration of its lead assets, CogniCann and CannEpil, and any other medicinal cannabis products currently being developed.

CannEpil is a cannabis-based medicine designed to regulate patients with epilepsy, and the company recently announced that the number of patients in Australia being subscribed their products had reached the 100-patient milestone. In addition, they also have a distribution agreement with Canvallate, one of Australia’s premier distribution companies.

MGC Pharmaceuticals very recently announced they had received commitments for AUD$4.75 million, and are using some of this capital to pursue a joint-listing on the London Stock Exchange (LSE). Exactly the kind of exposure required with their main operations and revenue coming from the European Union.

“we have rapidly advanced the business, delivering material results through ground-breaking research and development, increasing our distribution channels globally, and widening our growing and manufacturing capabilities.”

– Co-founder and Managing Director of MGC Pharma, Roby Zomer

They also have the cannabis industry’s leading brokerage house – Canaccord Genuity – acting as their equity capital markets partner to assist in the LSE listing. This would make MGC Pharma one of the very first to list on the UK exchange, in a market that is set to explode in the coming years.

The company is leveraging its Australian presence by looking to Asia for growth. Recently MGC Pharma secured a distribution deal with YuShop for their CBD-based nutraceutical range.

YuShop specialises in bring health and wellness products into China. YuShop then provides a cross-border digital commerce platform that allows their clients to import, market and sell to their more affluent Chinese customers. YuShop will provide MGC Pharma access to over 1,500 retail channel partners.

With their euGMP facility, multi-phase clinical studies on their unique medicine cannabis strains, and a first-mover advantage into the multi-billion dollar Chinese health and wellness market. A biotech with multi-channel commercial streams. We really like the story, and have a long-term position in the company.